In genomics, as in life, you need to be in the right place at the right time, and you need integrity, to be credible. Since the availability of the human genome sequence, there's been an explosion in genetic testing. And epigenetics is entering the clinic by measuring chemical modifications to DNA or proteins that influence gene expression. Tumor mutational burden and microsatellite instability assessments are used to try and better match patients to the right therapies. But basic cell biologists have known for years that the genome has a dynamic organization in the cell which influences its expression also. And with genomic instability as the hallmark of cancer, this nuclear organization too can become disrupted in disease. Our group has developed a platform that captures and evaluates the content and configuration of the genome in individual cells, and are bringing it to the clinic. By combining immunohistochemistry with telomere-FISH labelling, three-dimensional microscopy, and proprietary TeloView(TM) software analytics, distinct profiles are identified that can distinguish between disease severity, risk of disease progression, and likelihood of response to therapy. This technology establishes the dynamic organization of the genome as a novel universal biomarker paradigm. This session will cover some of the fundamental principles of this new approach, and its applications already in cancer and Alzheimer's disease.